Frontlight ResearchEarly access
WithdrawnNo phase
A Retrospective Study to Describe Real-World Treatment Patterns and Clinical Outcomes Among Patients With Myelodysplastic Syndromes
Key facts
- Who runs it
- Bristol-Myers Squibb
- Where
- Taiwan1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Started
- 30 Nov 2024
- Ended
- 30 Mar 2025
- Type of study
- Observational, 2 groups
- Treatments tested
- Luspatercept
- Epoetin Alfa
- Record updated
- 9 October 2024
- Why it stopped
- Sponsor decision
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Participant was enrolled in and discontinued the COMMANDS trial
- Participant was treated with either luspatercept or epoetin alfa and discontinued treatment while enrolled in the COMMANDS trial
- Participant Patient provides informed consent (only where applicable or required by local regulations)
Who cannot take part
- There are no exclusion criteria for this study
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study aims to collect real-world data on treatment patterns and clinical outcomes for participants who discontinued Luspatercept or epoetin alfa treatment and discontinued the COMMANDS trial (NCT03682536) utilizing existing data from patient medical records.
The 2 groups in the trial
- Luspatercept
Adult participants treated with and discontinued Luspatercept treatment while enrolled in the COMMANDS trial (NCT03682536).
- Epoetin alfa
Adult participants treated with and discontinued Epoetin alfa treatment while enrolled in the COMMANDS trial (NCT03682536).
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Retrospective Study to Describe Real-World Treatment Patterns and Clinical Outcomes Among Patients With Myelodysplastic Syndromes Who Discontinued Treatment With Luspatercept or Epoetin Alfa and the COMMANDS Trial
- Record updated
- 9 October 2024